ATE472334T1 - Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind - Google Patents

Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Info

Publication number
ATE472334T1
ATE472334T1 AT05716455T AT05716455T ATE472334T1 AT E472334 T1 ATE472334 T1 AT E472334T1 AT 05716455 T AT05716455 T AT 05716455T AT 05716455 T AT05716455 T AT 05716455T AT E472334 T1 ATE472334 T1 AT E472334T1
Authority
AT
Austria
Prior art keywords
modulating
polypeptide sequences
viral proteins
sequences involved
immunosuppressive effect
Prior art date
Application number
AT05716455T
Other languages
German (de)
English (en)
Inventor
Martial Renard
Marianne Mangeney
Thierry Heidmann
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE472334T1 publication Critical patent/ATE472334T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05716455T 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind ATE472334T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (1)

Publication Number Publication Date
ATE472334T1 true ATE472334T1 (de) 2010-07-15

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716455T ATE472334T1 (de) 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
CA2749183C (en) 2009-01-09 2017-11-28 Marc Sitbon New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20130260394A1 (en) * 2010-09-17 2013-10-03 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
AU2012350258B2 (en) * 2011-12-07 2017-03-02 Centre National De La Recherche Scientifique Mutated lentiviral ENV proteins and their use as drugs
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US9974852B2 (en) 2013-06-07 2018-05-22 Viroxis Sas Mutated non-primate lentiviral Env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および/または治療における使用のためのワクチン
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク. Arcベースのカプシドおよびその使用
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine
AU2024256799A1 (en) 2023-04-21 2025-11-06 Inprother Aps Improved expression of surface-displayed antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) * 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
WO2005095442A8 (en) 2006-11-02
CN1961001A (zh) 2007-05-09
AU2005229411A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
CN1961001B (zh) 2012-09-05
US8178657B2 (en) 2012-05-15
US20080008683A1 (en) 2008-01-10
DE602005022056D1 (de) 2010-08-12
JP2008506357A (ja) 2008-03-06
US8597657B2 (en) 2013-12-03
BRPI0509497A (pt) 2007-09-11
IL178205A (en) 2015-05-31
US20120189647A1 (en) 2012-07-26
EP1732585B1 (en) 2010-06-30
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
ES2347445T3 (es) 2010-10-29
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
EP1732585A1 (en) 2006-12-20
ZA200608178B (en) 2008-10-29
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
ATE472334T1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
PH12019500596B1 (en) Recombinant binding proteins and their use
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
ATE543506T1 (de) Methode zur stabilisierung von proteinen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
PH12022552935A1 (en) Stabilized coronavirus spike protein fusion proteins
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2020006671A (es) Proteinas de fusion.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
ATE542915T1 (de) Cst-ii-modifzierungen für erhöhte proteinexpression
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
ATE486128T1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
PH12022553417A1 (en) Stabilized corona virus spike protein fusion proteins
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
WO2006047728A3 (en) Bmp gene and fusion protein
TR200003695T2 (tr) Anjiyostatin bağlayıcı protein.
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties